Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: Seeking Alpha
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript Arbutus Biopharma Corporation (NASDAQ: ABUS Company Participants Pam Murphy - IR Consultant William Collier - President, CEO David Hastings - CFO & CAO Gaston Picchio - Chief Development Officer Michael Sofia - Chief Scientific Officer Conference Call Participants Keay Nakae - Chardan Jeffrey Tan - B. Riley FBR Operator Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation 2019 Second Quarter Financial Results and Corporate Update Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference is being recorded. I would not like to introduce your host for today's conference Pam Murphy. You may begin. Thank you, and good morning. On the call from the Arbutus executives team are Bill Collier, President
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Here's Why Arbutus (ABUS) Surged in Q3 [Yahoo! Finance]Yahoo! Finance
- Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors [Yahoo! Finance]Yahoo! Finance
- Whitefort Capital Sends Letter to Arbutus Biopharma Board of DirectorsBusiness Wire
- Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside ChatGlobeNewswire
- Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.MarketBeat
ABUS
Earnings
- 11/6/24 - Miss
ABUS
Sec Filings
- 12/6/24 - Form EFFECT
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- ABUS's page on the SEC website